BACKGROUND _ AIMS: The pathogenesis of the @entity3178 is unknown but may involve bacteria, an intestinal luminal antigen, and/or @entity792 . It was hypothesized that @entity19019 would resolve both @entity294 and @entity32 in @entity3178 because it possesses antidiarrheal, antibacterial, and anti-inflammatory properties. METHODS: Thirteen @entity1 with @entity3178 (7 with subepithelial collagen deposition and 6 without) were treated with eight chewable 262-mg @entity19019 tablets per day for 8 weeks. @entity1 recorded the frequency of bowel movements daily. Forty-eight-hour stool collections and flexible sigmoidoscopy with 24 biopsies were performed before and after treatment in each @entity1 . RESULTS: Twelve @entity1 completed the trial. Eleven @entity1 had a resolution of @entity294 and a reduction in fecal weight. The average time to respond was 2 weeks. In 9 @entity1 , @entity1960 resolved. When present before treatment, subepithelial collagen thickening disappeared. Those completing the trial experienced no side effects. Posttreatment follow-up for 7-28 months shows that 9 @entity1 remain well having undergone no further treatment, 2 are well but required retreatment, and 1 has continued @entity294 . CONCLUSIONS: @entity19019 treatment for 8 weeks is safe and well tolerated. This regimen appears to be efficacious for the treatment of @entity3178 and is worthy of further study in a controlled trial.

Efficacy of open-label XXXX for the treatment of @entity3178 .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['colonic inflammation'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity19019 :: ('MESH:C015715', 'Chemical') :: ['bismuth subsalicylate', 'Bismuth subsalicylate'] @entity3178 :: ('MESH:D046728', 'Disease') :: ['microscopic colitis syndrome', 'microscopic colitis'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmunity']
@entity19019 :: (MESH:C015715,Chemical) :: ['bismuth subsalicylate']
